




Mateon Therapeutics  
Investor Relations Department  
701 Gateway Blvd, Suite 210  
S. San Francisco, CA 94080  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

#### OT: MATN

Last Trade:	0.37
Trade Time:	3:54 PM ET Jun 26, 2017
Change:	-0.02  (-5.195%)
Day Range	0.35 - 0.39
52-Week Range	0.27 - 0.89
Volume	10,323,600

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

We are committed to leveraging our intellectual property and the product development expertise of our highly experienced management team to enable vascular targeted therapy to realize its true potential and to bring much needed new therapies for orphan oncology indications to cancer patients worldwide. We have a portfolio of preclinical and clinical stage candidates focused on areas of significant unmet need that we believe can bring significant value to our shareholders.

Our common stock is traded on the OTCQX Market under the symbol "MATN".

We are head... [\(more\)](#)

## Stock Quote



## Press Releases [\[ View all \]](#)

*Jun 12, 2017*

[Mateon Therapeutics Provides Update on its Clinical Trial Programs and Milestones](#)

*Jun 7, 2017*

[Mateon Therapeutics Receives FDA Fast Track Designation for OXi4503 in Patients with Acute Myeloid Leukemia](#)

*May 8, 2017*

[Mateon Provides Corporate Update and Reports First Quarter 2017 Financial Results](#)

*Apr 27, 2017*

[Mateon Therapeutics Announces Presentations at the Tumor Microenvironment Workshop](#)

*Apr 20, 2017*

[Mateon Announces Initiation of Investigator-Sponsored Phase 1 Study of CA4P in Combination with Everolimus in Neuroendocrine Tumors](#)

## Financials & Filings [\[ View all \]](#)

*Mar 30, 2017*

[Annual Report \(10-K\)](#)

*Apr 26, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 8, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 14, 2016*

[Quarterly Report \(10-Q\)](#)